HCWBHealthcare · BiotechnologyThe 1 Wall Street analysts covering HCW Biologics Inc. hold a median 12-month price target of $30 — +1276.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores HCW Biologics Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Volatility (15): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HCWB, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +1276.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 May 2026 | Maxim Group | Maintains | Buy | — |
| 28 May 2026 | Maxim Group | Maintains | Buy | $2.00 → $5.00 |
| 29 May 2025 | Maxim Group | Maintains | Buy | — |
| 1 June 2023 | EF Hutton | Assumes | Buy | $9.00 |
| 19 Apr 2023 | EF Hutton | Reiterates | Buy | — |
| 30 Mar 2023 | EF Hutton | Reiterates | Buy | — |
| 23 Mar 2023 | EF Hutton | Reiterates | Buy | — |
| 8 Nov 2022 | JonesTrading | Initiates | Buy | — |
| 24 Mar 2022 | Maxim Group | Initiates | Buy | — |
| 19 Nov 2021 | EF Hutton | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HCWB appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 76% of US stocks
Cheaper than 80% of US stocks
Cheaper than 87% of US stocks
Cheaper than 69% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 96% of US stocks
Higher than 12% of US stocks
Higher than 2% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own HCW Biologics Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
HCW Biologics reported its financial results and business highlights for the second quarter of 2026, covering the three and six months ended June 30, 2026.
Why it matters — This is a standard quarterly update that provides clinical development progress and financial performance for a clinical-stage biopharmaceutical company.
HCW Biologics announced the pricing of a $1.6 million private placement offering with a group of investors that includes officers, directors, and an existing stockholder. The offering consists of 618,682 units, each comprising one share of common stock (or a pre-funded warrant in lieu thereof) and a common stock purchase warrant.
Why it matters — The private placement represents a capital raise that involves existing insiders and will increase the company's outstanding share count, which is a notable financing event for the clinical-stage biopharmaceutical company.
The 1 Wall Street analysts covering HCW Biologics Inc. have a median 12-month price target of $30, with estimates ranging from $30 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering HCW Biologics Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HCW Biologics Inc. 66 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, HCW Biologics Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +1276.1% from the last close, and Ticker Nerd's factor model ranks HCW Biologics Inc. 66 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering HCW Biologics Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HCWB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $30 over the next 12 months.
HCW Biologics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel immunotherapies that target inflammaging—the chronic, low-grade inflammation linked to age-related diseases.
The most recent item we track (GlobeNewsWire, 14 Aug 2026): "HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results". HCW Biologics reported its financial results and business highlights for the second quarter of 2026, covering the three and six months ended June 30, 2026.
HCW Biologics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel immunotherapies that target inflammaging—the chronic, low-grade inflammation linked to age-related diseases. The company focuses on conditions including cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune disorders. HCW Biologics leverages two proprietary discovery platforms: TOBI™ (Tissue factOr-Based fusIon) and TRBC (T-cell Receptor β Chain constant region), which enable the design of multi-functional fusion molecules that simultaneously activate immune responses and target diseased cells. The company maintains a pipeline of over 50 molecules in development, with lead candidates currently advancing through clinical trials for oncology and autoimmune indications. HCW Biologics collaborates with key partners including Wugen Inc. for cell therapy manufacturing and maintains a joint venture with WY Biotech. Founded in 2018 and headquartered in Miramar, Florida, the company operates as a publicly traded entity pursuing immunotherapy innovation in the biopharmaceutical sector.
CEO Dr. Hing C. Wong Ph.D. · 35 employees · United States · https://www.hcwbiologics.com